DK2722332T3 - Quinolylpyrrolopyrimidylforbindelse med kondenseret ring eller salt deraf. - Google Patents

Quinolylpyrrolopyrimidylforbindelse med kondenseret ring eller salt deraf. Download PDF

Info

Publication number
DK2722332T3
DK2722332T3 DK13745327.0T DK13745327T DK2722332T3 DK 2722332 T3 DK2722332 T3 DK 2722332T3 DK 13745327 T DK13745327 T DK 13745327T DK 2722332 T3 DK2722332 T3 DK 2722332T3
Authority
DK
Denmark
Prior art keywords
compound
amino
quinolin
formula
pyrrolo
Prior art date
Application number
DK13745327.0T
Other languages
English (en)
Inventor
Takeshi Sagara
Satoru Ito
Sachie Otsuki
Katsumasa Nonoshita
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK2722332T3 publication Critical patent/DK2722332T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (9)

1. Forbindelse repræsenteret ved den følgende Formel (I)
(I) eller et salt deraf, hvor m er 1 eller 2; n er 1 eller 2; Ri er et hydrogenatom eller en Ci-C4-alkylgruppe; og R2, R3, og R4 er ens eller forskellige, og hvert er et hydrogenatom, et halogenatom, en Ci-C4-alkylgruppe, eller en gruppe repræsenteret ved Formel (a): -CH2-N(R5) (Re) (a) hvor R5 og R5 er ens eller forskellige og hvert repræsenterer et hydrogenatom eller en Ci-C4-alkylgruppe, eller R5 og R6 kan danne en heterocycloalkylgruppe, der har en 4 til 6-leddet ring, sammen med nitrogenatomet bundet dertil.
2. Forbindelse eller et salt deraf ifølge krav 1, hvor m er 1 eller 2; n er 1 eller 2; Ri er et hydrogenatom eller en Ci-C4-alkylgruppe; og R2, R3, og R4 er ens eller forskellige, og hvert er et hydrogenatom, et halogenatom, en Ci-C4-alkylgruppe, eller en gruppe repræsenteret ved Formel (a): -CH2-N(R5) (R6) (a) hvor R5 og R6 er ens eller forskellige og hvert repræsenterer en Ci-C4-alkylgruppe.
3. Forbindelse eller et salt deraf ifølge krav 1 eller 2, hvor m er 1 eller 2; n er 1 eller 2; Ri er et hydrogenatom eller methylgruppe; og R2, R3, og R4 er ens eller forskellige, og hvert er et hydrogenatom, et chloratom, eller en dimethylaminomethylgruppe.
4. Forbindelse eller et salt deraf ifølge et hvilket som helst af krav 1 til 3, hvor m og n er (m, n) = (1,1), (1,2), eller (2,1).
5. Forbindelse eller et salt deraf ifølge et hvilket som helst af krav 1 til 4, hvor forbindelsen er valgt blandt den følgende gruppe af forbindelser: (R)-N-(4-amino-5-(quinolin-3-yl)-6,7,8,9-tetrahydropyrimido[5,4-b]indolizin-8- yl)acrylamid, (S)-N-(4-amino-5-(quinolin-3-yl)-6,7,8,9-tetrahydropyrimido[5,4-b]indolizin-8- yl)acrylamid, N-(4-amino-5-(quinolin-3-yl)-6,7,8,9-tetrahydropyrimido[5,4-b]indolizin-8-yl)-N- methylacrylamid, (E)-N-(4-amino-5-(quinolin-3-yl)-6,7,8,9-tetrahydropyrimido[5,4-b]indolizin-8-yl)-4- (dimethylamino)-2-butenamid, (S,E)-N-(4-amino-5-(quinolin-3-yl)-6,7,8,9-tetrahydropyrimido[5,4-b]indolizin-8-yl)- 3-chloracrylamid, (S,Z)-N-(4-amino-5-(quinolin-3-yl)-6,7,8,9-tetrahydropyrimido[5,4-b]indolizin-8-yl)- 3-chloracrylamid, (S)-N-(4-amino-5-(quinolin-3-yl)-7,8,9,10-tetrahydro-6H- pynmidotS'^'^^JpyrroloCl^-aJazepin-S-yOacrylamid, (S)-N-(4-amino-5-(quinolin-3-yl)-7,8,9,10-tetrahydro-6H-ργΝπ^ο[5,,4':4,5]pyrrolo[l,2-a]azepin-9-yl)acrylamid, og (R)-N-(4-amino-5-(quinolin-3-yl)-7,8,9,10-tetrahydro-6H-pyrinnido[5,,4':4,5]pyrrolo[l,2-a]azepin-9-yl)acrylamid.
6. Forbindelse eller et salt deraf ifølge et hvilket som helst af krav 1 til 5 til anvendelse som en EGFR-inhibitor.
7. Farmaceutisk sammensætning omfattende forbindelsen eller et salt deraf ifølge et hvilket som helst af krav 1 til 5.
8. Forbindelse eller et salt deraf ifølge et hvilket som helst af krav 1 til 5 til anvendelse som et antitumormiddel.
9. Forbindelse eller et salt deraf ifølge et hvilket som helst af krav 1 til 5 til anvendelse i behandlingen eller forebyggelsen af cancer.
DK13745327.0T 2012-02-23 2013-02-22 Quinolylpyrrolopyrimidylforbindelse med kondenseret ring eller salt deraf. DK2722332T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012037565 2012-02-23
PCT/JP2013/054615 WO2013125709A1 (ja) 2012-02-23 2013-02-22 キノリルピロロピリミジル縮合環化合物又はその塩

Publications (1)

Publication Number Publication Date
DK2722332T3 true DK2722332T3 (da) 2016-06-20

Family

ID=49005885

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13745327.0T DK2722332T3 (da) 2012-02-23 2013-02-22 Quinolylpyrrolopyrimidylforbindelse med kondenseret ring eller salt deraf.

Country Status (15)

Country Link
US (1) US8889666B2 (da)
EP (1) EP2722332B1 (da)
JP (1) JP5557963B2 (da)
KR (1) KR101660145B1 (da)
CN (1) CN104136438B (da)
CA (1) CA2861980C (da)
DK (1) DK2722332T3 (da)
ES (1) ES2580530T3 (da)
HU (1) HUE029343T2 (da)
MX (1) MX351863B (da)
PL (1) PL2722332T3 (da)
RU (1) RU2581039C1 (da)
SG (1) SG11201402876UA (da)
TW (1) TWI496783B (da)
WO (1) WO2013125709A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150119401A (ko) * 2013-02-22 2015-10-23 다이호야쿠힌고교 가부시키가이샤 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물
BR112016003247B1 (pt) * 2013-08-22 2022-05-10 Taiho Pharmaceutical Co., Ltd Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso
PT3279202T (pt) * 2015-03-31 2020-08-31 Taiho Pharmaceutical Co Ltd Cristal de composto de alquinilo de benzeno 3,5-dissubstituído
WO2017064558A1 (ja) * 2015-10-14 2017-04-20 大鵬薬品工業株式会社 新規免疫賦活化剤
WO2018079310A1 (ja) 2016-10-31 2018-05-03 大鵬薬品工業株式会社 エクソン２０挿入変異型ｅｇｆｒ選択的阻害剤
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
PL3677266T3 (pl) 2017-09-01 2024-07-01 Taiho Pharmaceutical Co., Ltd. Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21
CN115181104A (zh) * 2019-09-29 2022-10-14 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN115785107B (zh) * 2022-12-15 2024-11-12 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1871773A1 (en) * 2005-03-17 2008-01-02 Novartis AG N-[3-(1-amino-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yl)-phenyl]benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
JP2009520028A (ja) * 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｉｇｆｒ抑制剤および抗癌剤の併用
WO2007114926A2 (en) * 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
WO2008018881A1 (en) * 2006-08-10 2008-02-14 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
DK2526933T3 (da) * 2006-09-22 2015-05-18 Pharmacyclics Inc Hæmmere af Brutons tyrosinkinase
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN102146059A (zh) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 喹唑啉衍生物、制备方法及其应用
MX342164B (es) * 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
EP2635284B1 (en) * 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
EP2722332B1 (en) 2016-04-20
TWI496783B (zh) 2015-08-21
PL2722332T3 (pl) 2016-10-31
JP5557963B2 (ja) 2014-07-23
CN104136438A (zh) 2014-11-05
SG11201402876UA (en) 2014-12-30
US8889666B2 (en) 2014-11-18
CN104136438B (zh) 2016-04-06
CA2861980C (en) 2016-11-08
EP2722332A1 (en) 2014-04-23
HUE029343T2 (en) 2017-02-28
MX351863B (es) 2017-10-30
TW201339160A (zh) 2013-10-01
CA2861980A1 (en) 2013-08-29
EP2722332A4 (en) 2014-04-23
US20140057899A1 (en) 2014-02-27
JPWO2013125709A1 (ja) 2015-07-30
WO2013125709A1 (ja) 2013-08-29
AU2013223052A1 (en) 2014-07-03
RU2581039C1 (ru) 2016-04-10
MX2014009991A (es) 2014-09-08
ES2580530T3 (es) 2016-08-24
HK1202862A1 (zh) 2015-10-09
KR101660145B1 (ko) 2016-09-26
KR20140117647A (ko) 2014-10-07

Similar Documents

Publication Publication Date Title
DK2722332T3 (da) Quinolylpyrrolopyrimidylforbindelse med kondenseret ring eller salt deraf.
AU2014309788B2 (en) Novel quinoline-substituted compound
WO2013118817A1 (ja) キノリルピロロピリミジン化合物又はその塩
RU2797117C2 (ru) Новое хинолин-замещенное соединение
HK1202862B (en) Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof
HK1222393B (en) Quinoline-substituted compound